VRCA
NASDAQVerrica Pharmaceuticals Inc.
Price$5.75+0.36 (+6.58%)
2026-03-022026-06-03
News · 26 weeks33+75%
2025-12-072026-05-31
Mix1790d
- SEC Filings7(41%)
- Earnings3(18%)
- Offering3(18%)
- Other3(18%)
- Analyst1(6%)
Latest news
25 items- PRVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceWEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference. Jefferies Global Healthcare Conference, June 2-4, 2026Event details:Date: Thursday, June 4, 2026Time: 11:05am ETLocation: New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Eve
- ANALYSTH.C. Wainwright resumed coverage on Verrica Pharmaceuticals with a new price targetH.C. Wainwright resumed coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $12.00
- PRVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQWEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026Event details:Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can a
- SECSEC Form S-8 filed by Verrica Pharmaceuticals Inc.S-8 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form 10-Q filed by Verrica Pharmaceuticals Inc.10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Reports First Quarter 2026 Financial Results– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the second trial in the US and Japan in mid-2026 – – Company reports total revenue of $5.0 million in Q1 2026, including U.S. YCANTH net product revenue of $4.3 million in Q1 2026, up 16.2% over previous quarter and 25.4% year-over-year – – YCANTH commercial launch in Japan by partner Torii Pharmaceu
- PRVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingPhase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.
- PRVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10
- SECSEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form DEF 14A filed by Verrica Pharmaceuticals Inc.DEF 14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingWEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica's novel oncolytic peptide for the treatment of basal cell carcinoma. The data will be presented at the upcoming 2026 Society for Investigative Dermatology (SID) Annual Meeting, which will take place from May 13-16, 2026, in Chicago, Illinois. Presentation Details: Title: "VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Targ
- PRVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceWEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026Event details:Date: Wednesday, April 15, 2026Time: 3:00pm ETLocation: Virtual Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the I
- SECSEC Form 10-K filed by Verrica Pharmaceuticals Inc.10-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate
- PRVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di
- PRVerrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceWEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday, March 2, 2026Time: 10:30am ETLocation: Boston, Massachusetts Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/P
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.SCHEDULE 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
- PRVerrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial OfficerWEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. "It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. "Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and co
- PRVerrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii PharmaceuticalWEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. ("Torii"), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum ("molluscum"). "We would like to congratulate our partner, Torii, on the launch of YCANTH in Japan for the treatment of molluscum. Torii's achievement also represents an exciting milestone for Verrica, as we continue to execute on our long-term strategy of developing a
- INSIDERAmendment: SEC Form 3 filed by new insider Bkb Growth Investments, Llc3/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERNew insider Bkb Growth Investments, Llc claimed ownership of 3,348,372 shares (SEC Form 3)3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- PRVerrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. "The
- INSIDERInterim CFO Kirby John J. was granted 10,000 shares, increasing direct ownership by 112% to 18,962 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
VRCA FAQ
7 questionsWhat does Verrica Pharmaceuticals Inc. do?
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for...Where does VRCA stock trade?
Verrica Pharmaceuticals Inc. (VRCA) is listed on NASDAQ.What sector and industry is VRCA in?
Verrica Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verrica Pharmaceuticals Inc. go public?
Verrica Pharmaceuticals Inc. (VRCA) completed its IPO in 2018.What are analysts saying about VRCA?
Verrica Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2026-05-26. Recent price targets range from $400.00 to $2000.00.What companies are similar to VRCA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VRCA side-by-side with any of them on Quantisnow.How can I track VRCA on Quantisnow?
Quantisnow aggregates Verrica Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRCA to receive live email and push alerts on every new disclosure.